Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The treatment of adolescents and young adults with acute lymphoblastic leukemia.

Advani AS, Hanna R.

Leuk Lymphoma. 2019 Aug 27:1-9. doi: 10.1080/10428194.2019.1658103. [Epub ahead of print]

PMID:
31452423
2.

Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults.

Friend BD, Schiller GJ.

Blood Rev. 2018 Mar;32(2):122-129. doi: 10.1016/j.blre.2017.09.005. Epub 2017 Sep 21. Review.

PMID:
28969872
3.

Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia.

Orellana-Noia VM, Douvas MG.

Curr Hematol Malig Rep. 2018 Apr;13(2):100-108. doi: 10.1007/s11899-018-0442-1. Review.

PMID:
29442287
4.
5.

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.

Vairy S, Garcia JL, Teira P, Bittencourt H.

Drug Des Devel Ther. 2018 Nov 12;12:3885-3898. doi: 10.2147/DDDT.S138765. eCollection 2018. Review.

6.

[Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes].

Zuo YX, Jia YP, Wu J, Wang JB, Lu AD, Dong LJ, Chang LJ, Zhang LP.

Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):270-275. doi: 10.3760/cma.j.issn.0253-2727.2019.04.002. Chinese.

PMID:
31104436
7.

Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.

Muffly L, Lichtensztajn D, Shiraz P, Abrahão R, McNeer J, Stock W, Keegan T, Gomez SL.

Cancer. 2017 Jan 1;123(1):122-130. doi: 10.1002/cncr.30322. Epub 2016 Sep 13.

8.

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.

Pehlivan KC, Duncan BB, Lee DW.

Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x. Review.

PMID:
30120708
9.

A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.

DasGupta RK, Marini BL, Rudoni J, Perissinotti AJ.

J Oncol Pharm Pract. 2018 Sep;24(6):453-467. doi: 10.1177/1078155217713363. Epub 2017 Jun 5. Review.

PMID:
28583018
10.

Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.

Hochberg J, El-Mallawany NK, Cairo MS.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S6-13. doi: 10.1016/j.clml.2014.04.015. Review.

PMID:
25486958
11.

Are CAR T cells better than antibody or HCT therapy in B-ALL?

Pulsipher MA.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):16-24. doi: 10.1182/asheducation-2018.1.16. Review.

PMID:
30504287
12.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

13.

Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study.

Muffly L, Alvarez E, Lichtensztajn D, Abrahão R, Gomez SL, Keegan T.

Blood Adv. 2018 Apr 24;2(8):895-903. doi: 10.1182/bloodadvances.2017014944.

14.

Acute lymphoblastic leukemia in adolescents and young adults.

Burke PW, Douer D.

Acta Haematol. 2014;132(3-4):264-73. doi: 10.1159/000360204. Epub 2014 Sep 10. Review.

PMID:
25228551
15.

How I treat acute lymphoblastic leukemia in older adolescents and young adults.

Curran E, Stock W.

Blood. 2015 Jun 11;125(24):3702-10. doi: 10.1182/blood-2014-11-551481. Epub 2015 Mar 24. Review. Erratum in: Blood. 2015 Oct 8;126(15):1868. Dosage error in article text.

16.

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM.

Cancer. 2014 Dec 1;120(23):3660-8. doi: 10.1002/cncr.28930. Epub 2014 Jul 17.

17.

Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Mohan SR, Advani AS.

J Adolesc Young Adult Oncol. 2011 Mar;1(1):19-24. doi: 10.1089/jayao.2010.0001.

PMID:
26812565
18.

Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis.

Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P.

Am J Hematol. 2012 May;87(5):472-8. doi: 10.1002/ajh.23149. Epub 2012 Mar 3. Review.

19.

High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.

Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, Wu YN, Deng ZL, Zhang YL, Liu SH, Wu T, Lu PH, Lu DP, Chang AH, Tong CR.

Leukemia. 2017 Dec;31(12):2587-2593. doi: 10.1038/leu.2017.145. Epub 2017 May 15.

PMID:
28490811
20.

Supplemental Content

Support Center